

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse IGFBP-L1 in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross-reactivity with recombinant human IGFBP-L1 is observed and less than 1% cross-reactivity with recombinant mouse IGFBP-7 is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse IGFBP-L1 Leu18-Leu270 Accession # Q80W15
Conjugate	Alexa Fluor 647 Excitation Wavelength: 650 nm Emission Wavelength: 668 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunohistochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Insulin-like Growth Factor Binding Protein-Like 1 (IGFBP-L1), also known as IGFBP-rP4, is a 38 kDa secreted member of the IGFBP superfamily of proteins. IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins (1). IGFBP-L1 contains an N-terminal IGFBP motif, a Kazal-type serine protease inhibitor region, and a C-terminal Ig-like domain (2, 3). Mature mouse IGFBP-L1 shares 76% and 96% amino acid (aa) sequence identity with human and rat IGFBP-L1, respectively. It shares 38%-41% aa sequence identity with mouse IGFBP-7 and IGFBP-rp10 and 20%-24% aa sequence identity with mouse IGFBP-1, -2, -3, -4, -5, and -6. IGFBP-L1 is most highly expressed in testis and brain, while lower levels are more broadly expressed (3). IGFBP-L1 is expressed in regionally and temporally distinct patterns during forebrain development (4). IGFBP-L1 inhibits cell proliferation in vitro and is downregulated in many colon and lung tumors (3). Transcriptional downregulation by promoter methylation is predictive of breast cancer aggressiveness (5).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.